›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:OncoSTRAT&GO
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
OncoDNAType:
CE Marked
Related tests:
OncoSTRAT&GO an integrated approach that combines the analyses of a solid biopsy (by the next-generation sequencing of 313 genes, IHCs and additional tests) with the analysis of a blood biopsy. The blood profiling focuses either on the circulating tumor DNA (for deciphering tumor heterogeneity) or in DNA from blood cells (for studying specific germline gene alterations related to BRCAness phenotype that are challenging to detect in FFPE samples). OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, hormonal therapies, chemotherapies and immunotherapies.
Cancer:
Colorectal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Triple Negative Breast Cancer
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), ARID1A (AT-rich interaction domain 1A)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), ARID1A (AT-rich interaction domain 1A), ARID2 (AT-Rich Interaction Domain 2), ATM (ATM serine/threonine kinase), AXIN1 (Axin 1), BCL2 (B-cell CLL/lymphoma 2), BCOR (BCL6 Corepressor), BIRC2 (Baculoviral IAP Repeat Containing 2), BIRC3 (Baculoviral IAP repeat containing 3), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CASP8 (Caspase 8), CCND1 (Cyclin D1), CCND2 (Cyclin D2), CCND3 (Cyclin D3), CCNE1 (Cyclin E1), CD44 (CD44 Molecule), CD70 (CD70 Molecule), CDK4 (Cyclin-dependent kinase 4), CDK6 (Cyclin-dependent kinase 6), CEBPA (CCAAT Enhancer Binding Protein Alpha), EGFR (Epidermal growth factor receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), FANCC (FA Complementation Group C), FANCL (FA Complementation Group L), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FGFR4 (Fibroblast growth factor receptor 4), FLT3 (Fms-related tyrosine kinase 3), FLT4 (Fms-related tyrosine kinase 4), FOXA1 (Forkhead Box A1), FOXA2 (Forkhead Box A2), GATA1 (GATA Binding Protein 1), GATA2 (GATA Binding Protein 2), GATA3 (GATA binding protein 3), GATA6 (GATA Binding Protein 6), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), IL6 (Interleukin 6), JAK1 (Janus Kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), KIT (KIT proto-oncogene, receptor tyrosine kinase), KMT2A (Lysine Methyltransferase 2A), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAPK1 (Mitogen-activated protein kinase 1), MET (MET proto-oncogene, receptor tyrosine kinase), MYC (V-myc avian myelocytomatosis viral oncogene homolog), NOTCH1 (Notch 1), NOTCH2 (Notch 2), NOTCH3 (Notch Receptor 3), NRAS (Neuroblastoma RAS viral oncogene homolog), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), PD-1 (Programmed cell death 1), PD-L1 (Programmed death ligand 1), PD-L2 (Programmed Cell Death 1 Ligand 2), POLE (DNA Polymerase Epsilon), PTCH1 (Patched 1), PTEN (Phosphatase and tensin homolog), RAD50 (RAD50 Double Strand Break Repair Protein), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), SMAD2 (SMAD Family Member 2), SMAD4 (SMAD family member 4), STAT3 (Signal Transducer And Activator Of Transcription 3), mTOR (Mechanistic target of rapamycin kinase)
Method:
Next-Generation Sequencing (NGS)
